Sagimet Biosciences will present at three investor conferences addressing its metabolic drug candidates and ongoing clinical trials.
Quiver AI Summary
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and fibrotic diseases, announced its participation in three upcoming investor conferences: the H.C. Wainwright Liver Disease Virtual Conference on October 21-22, the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, and the UBS Global Healthcare Conference on November 11. The fireside chats from the first two conferences will be available for viewing on Sagimet's website. The company is advancing its lead drug candidate, denifanstat, an oral FASN inhibitor for treating metabolic dysfunction associated with steatohepatitis, which has received FDA Breakthrough Therapy designation. Additionally, Sagimet has launched a Phase 1 clinical trial for a combination therapy of denifanstat and resmetirom, and another trial for its second FASN inhibitor, TVB-3567, aimed at treating acne. For more details, interested parties can visit Sagimet's website.
Potential Positives
- Sagimet Biosciences will participate in three upcoming investor conferences, which can enhance visibility and attract potential investment opportunities.
- The successful completion of the Phase 2b clinical trial for denifanstat with positive results is a significant milestone, demonstrating the efficacy of its lead drug candidate.
- Denifanstat has received Breakthrough Therapy designation from the FDA, indicating that it has the potential to offer significant benefits over existing therapies for non-cirrhotic MASH with moderate to advanced liver fibrosis.
- The initiation of a Phase 1 clinical trial for a combination treatment of denifanstat and resmetirom, as well as another Phase 1 trial for a second drug candidate, demonstrates ongoing innovation and expansion of Sagimet's product pipeline.
Potential Negatives
- The press release mainly highlights participation in upcoming investor conferences rather than providing updates on the company's business progress or developments, which may indicate a lack of substantive news.
- The inclusion of multiple conferences suggests a possible need for increased visibility and investor engagement, potentially indicating challenges in investor confidence or outreach.
FAQ
What upcoming conferences will Sagimet Biosciences participate in?
Sagimet will attend the H.C. Wainwright Liver Disease Virtual Conference, Guggenheim Healthcare Innovation Conference, and UBS Global Healthcare Conference.
When is the H.C. Wainwright Liver Disease Virtual Conference?
The conference will take place on October 21-22, 2025, starting with a fireside chat at 7am ET on October 21.
Where can I watch Sagimet's fireside chats?
The fireside chats will be available in the Investors & Media section of Sagimet’s website, with archived replays for 90 days.
What is Sagimet's lead drug candidate?
Sagimet's lead drug candidate is denifanstat, an oral selective FASN inhibitor for metabolic dysfunction associated with steatohepatitis (MASH).
What recent trial has Sagimet completed successfully?
Sagimet successfully completed the Phase 2b clinical trial of denifanstat for MASH, showing positive results with liver biopsy-based primary endpoints.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SGMT Insider Trading Activity
$SGMT insiders have traded $SGMT stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $SGMT stock by insiders over the last 6 months:
- DAVID HAPPEL (President & CEO) sold 65,478 shares for an estimated $598,115
- ELIZABETH ROZEK (General Counsel and CCO) sold 10,780 shares for an estimated $98,470
- EDUARDO BRUNO MARTINS (Chief Medical Officer) sold 8,277 shares for an estimated $75,607
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SGMT Hedge Fund Activity
We have seen 32 institutional investors add shares of $SGMT stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WOODLINE PARTNERS LP added 2,552,536 shares (+inf%) to their portfolio in Q2 2025, for an estimated $19,450,324
- POINT72 ASSET MANAGEMENT, L.P. removed 1,755,143 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $13,374,189
- ALYESKA INVESTMENT GROUP, L.P. removed 1,192,443 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $9,086,415
- ROCK SPRINGS CAPITAL MANAGEMENT LP removed 787,808 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,003,096
- PFM HEALTH SCIENCES, LP removed 559,006 shares (-86.1%) from their portfolio in Q2 2025, for an estimated $4,259,625
- BLACKROCK, INC. removed 487,741 shares (-50.2%) from their portfolio in Q2 2025, for an estimated $3,716,586
- BRIDGEWAY CAPITAL MANAGEMENT, LLC added 288,341 shares (+231.6%) to their portfolio in Q2 2025, for an estimated $2,197,158
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SGMT Analyst Ratings
Wall Street analysts have issued reports on $SGMT in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 10/02/2025
- Wedbush issued a "Outperform" rating on 08/11/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/07/2025
- Jones Trading issued a "Buy" rating on 06/06/2025
To track analyst ratings and price targets for $SGMT, check out Quiver Quantitative's $SGMT forecast page.
$SGMT Price Targets
Multiple analysts have issued price targets for $SGMT recently. We have seen 4 analysts offer price targets for $SGMT in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Edward Nash from Canaccord Genuity set a target price of $28.0 on 10/02/2025
- Yun Zhong from Wedbush set a target price of $28.0 on 08/11/2025
- Brandon Folkes from HC Wainwright & Co. set a target price of $29.0 on 08/07/2025
- Debanjana Chatterjee from Jones Trading set a target price of $27.0 on 06/06/2025
Full Release
SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in three upcoming investor conferences.
- H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025, with a fireside chat available starting October 21 at 7am ET (link here ).
- Guggenheim 2 nd Annual Healthcare Innovation Conference in Boston, MA, on November 10, 2025, with a fireside chat at 11:30am ET (link here ).
-
UBS Global Healthcare Conference in Palm Beach, FL, on November 11, 2025.
The HC Wainwright and Guggenheim fireside chats will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com , with an archived replay available for 90 days following the live events.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into further development. Sagimet has recently initiated a Phase 1 pharmacokinetic (PK) clinical trial of a combination of denifanstat and resmetirom that is planned to be developed for patients living with MASH. Sagimet has also initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne for the U.S. For additional information about Sagimet, please visit www.sagimet.com .
Investor Contact:
Joyce Allaire
LifeSci Advisors
[email protected]
Media Contact:
Michael Fitzhugh
LifeSci Advisors
[email protected]